Literature DB >> 9086004

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.

R L Dedrick1, M F Flessner.   

Abstract

Both theory and clinical studies demonstrate that drug concentrations in the peritoneal cavity can greatly exceed concentrations in the plasma following intraperitoneal administration. This regional advantage has been associated with clinical activity, including surgically documented complete responses in ovarian cancer patients with persistent or recurrent disease following systemic therapy, and has produced a survival advantage in a recent phase III trial. Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration by the drug and incomplete irrigation of serosal surfaces by the drug-containing solution. We have examined these problems in the context of a very simple, spatially distributed model. If D is the diffusivity of the drug in a tissue adjacent to the peritoneal cavity and k is the rate constant for removal of the drug from the tissue by capillary blood, the model predicts that (for slowly reacting drugs) the characteristic penetration distance is (D/k)1/2 and the apparent permeability of the surface of a peritoneal structure is (Dk)1/2. The permeability-area product used in classical pharmacokinetic calculations for the peritoneal cavity as a whole is the sum of the products of the tissue-specific permeabilities and the relevant superficial surface areas. Since the model is mechanistic, it provides insight into the expected effect of procedures such as pharmacologic manipulation or physical mixing. We observe that large changes in tissue penetration may be difficult to achieve but that we have very little information on the transport characteristics within tumors in this setting or their response to vasoactive drugs. Enhanced mixing is likely to offer significant potential for improved therapy; however, procedures easily applicable to the clinical setting have not been adequately investigated and should be given high priority. Clinical studies indicate that an increase in irrigated area may be achieved in many patients by individualizing the dialysate volume and consideration of patient position.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086004     DOI: 10.1093/jnci/89.7.480

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  75 in total

1.  Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator.

Authors:  M A Reymond; B Hu; A Garcia; T Reck; F Köckerling; J Hess; P Morel
Journal:  Surg Endosc       Date:  2000-01       Impact factor: 4.584

2.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

3.  Office-based intraperitoneal chemotherapy for ovarian cancer.

Authors:  William R Robinson; Cathy Coberly; Julie Beyer; April Lewis; Carrie Ballard
Journal:  J Oncol Pract       Date:  2008-09       Impact factor: 3.840

4.  Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).

Authors:  Koen P Rovers; Emma C E Wassenaar; Robin J Lurvink; Geert-Jan M Creemers; Jacobus W A Burger; Maartje Los; Clément J R Huysentruyt; Gesina van Lijnschoten; Joost Nederend; Max J Lahaye; Maarten J Deenen; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh
Journal:  Ann Surg Oncol       Date:  2021-02-05       Impact factor: 5.344

5.  Description of a novel approach for intraperitoneal drug delivery and the related device.

Authors:  Wiebke Solaß; Alexander Hetzel; Giorgi Nadiradze; Emil Sagynaliev; Marc A Reymond
Journal:  Surg Endosc       Date:  2012-05-12       Impact factor: 4.584

Review 6.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

7.  Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Authors:  Dhaval K Shah; Beom Soo Shin; Jean Veith; Karoly Tóth; Ralph J Bernacki; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2009-02-20       Impact factor: 4.030

8.  Site-Specific In Vivo Bioorthogonal Ligation via Chemical Modulation.

Authors:  Heebeom Koo; Jeong Heon Lee; Kai Bao; Yunshan Wu; Georges El Fakhri; Maged Henary; Seok Hyun Yun; Hak Soo Choi
Journal:  Adv Healthc Mater       Date:  2016-08-29       Impact factor: 9.933

9.  Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

Authors:  Ian R Corbin; Kenneth K Ng; Lili Ding; Andrea Jurisicova; Gang Zheng
Journal:  Nanomedicine (Lond)       Date:  2012-10-15       Impact factor: 5.307

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.